We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50 | -5.17% | 27.50 | 27.00 | 28.00 | 29.00 | 27.50 | 29.00 | 248,283 | 11:00:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Services, Nec | 3.4M | -46.22M | -0.4626 | -0.59 | 27.48M |
From Apr 2019 to Apr 2024
TIDMRENX
RNS Number : 8706L
Renalytix AI PLC
02 January 2019
Renalytix AI PLC
("RenalytixAI" or the "Company")
Exercise of Option for Exclusive License to Kidney Transplant Diagnostic Technology
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostics solutions for kidney disease, announces the exercise of its option, as described in the Company's admission document, for the exclusive license from the Icahn School of Medicine at Mount Sinai ("ISMMS") of a portfolio of diagnostics (referred to as FractalDX) focused on kidney transplant.
The portfolio consists of data, development and intellectual property across different diagnostic indications including identification of post-transplant / sub-clinical acute rejection, prediction of fibrosis / graft survival and pre-transplant / immune stratification. The Company believes the ISMMS kidney transplant product portfolio has significant potential to address critical unmet needs in the kidney transplant field such as transplant donor / recipient status, and determining specific immunosuppression therapy levels for patients in the United States and globally.
As previously indicated, the terms of the exercise include a $1.0 million upfront exclusive license payment and reimbursement of intellectual property legal and other fees of approximately $0.3 million to ISMMS. The license agreement is subject to certain milestone, royalty and maintenance payments as the Company progresses through the process of commercialisation and into product sales. The Company will undertake further evaluation of the data and the optimal product commercialisation strategy for the FractalDX portfolio, and will comment further as and when appropriate.
Enquiries:
Hot Features
Premium
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR or Tel: +1 646
397 3970
--------------------------------------------
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
----------------------
Aubrey Powell / James White / George Tzimas
(Corporate Finance)
----------------------
Tom Salvesen / Mia Gardner (Corporate Broking)
----------------------
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
-----------------------------------------------------
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
---------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCMMGGMMZZGLZG
(END) Dow Jones Newswires
January 02, 2019 02:00 ET (07:00 GMT)
1 Year Renalytix Chart |
1 Month Renalytix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
